Attributed 2025 performance to improved commercial execution and record SUBLOCADE net revenue of $856 million, a 13% ...

Q4 2025 Management View CEO Joseph Ciaffoni stated that 2025 was a transition year, highlighting the successful completion of Phase I Generate Momentum and the delivery of record net revenue for ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, ...

Thanks, Jason, good morning and thank you for joining us on today's call to review our fourth quarter and full year 2025 ...

Indivior PLC is set to report fourth-quarter and full-year 2025 results before the market opens Thursday, February 26, as Wall Street looks for evidence the addiction-treatment specialist can deliver ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...

SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered ...

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- ...

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...